A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors

Maxime Chénard-Poirier,Aaron R. Hansen,Martin E. Gutierrez,Drew Rasco,Yan Xing,Lin-Chi Chen,Heng Zhou,Andrea L. Webber,Tomoko Freshwater,Manish R. Sharma

DOI: https://doi.org/10.1007/s10637-024-01428-0

2024-03-15

Investigational New Drugs

Abstract:MEK inhibitors have immunomodulatory activity and potential for synergistic activity when combined with PD-1 inhibitors. We evaluated selumetinib (inhibitor of MEK1/2) plus pembrolizumab (anti‒PD-1 antibody) in patients with advanced/metastatic solid tumors. In this phase 1b study, adults with previously treated advanced/metastatic solid tumors received pembrolizumab 200 mg intravenously every 3 weeks plus selumetinib on days 1‒14 per 3-week cycle (2 weeks on/1 week off); selumetinib dosing began at 50 mg orally twice daily with escalation in 25 mg increments for ≤ 35 cycles. Primary endpoints were dose-limiting toxicities (DLTs), adverse events (AEs), and treatment discontinuations due to AEs. Thirty-two patients were enrolled. Dose escalation was completed up to selumetinib 125 mg twice daily. The target DLT rate of 30% was not reached at any dose level. In the selumetinib 100 mg group, 2/11 patients (18.2%) experienced DLTs (n = 1 grade 3 diarrhea, n = 1 grade 3 fatigue). In the selumetinib 125 mg group, 3/14 (21.4%) experienced DLTs (n = 1 grade 2 retinal detachment, n = 1 grade 3 retinopathy, n = 1 grade 3 stomatitis). Dose-related changes in pharmacokinetic exposures were observed for selumetinib and N -desmethyl selumetinib up to 100 mg (saturation at 125 mg). Two patients achieved partial responses (1 each with selumetinib 75 mg and 125 mg) for an objective response rate of 6%. The study was stopped early because of insufficient efficacy. Although the target DLT rate was not reached at any dose level and no new safety signals were identified, selumetinib plus pembrolizumab had limited antitumor activity in this population. Trial registration: ClinicalTrials.gov, NCT03833427.

oncology,pharmacology & pharmacy

What problem does this paper attempt to address?

This paper aims to evaluate the safety, tolerability, and preliminary anti - tumor activity of the MEK inhibitor Selumetinib in combination with the anti - PD - 1 antibody Pembrolizumab in patients with advanced or metastatic solid tumors. Specifically, the research objectives include:

1. **Dose - Limiting Toxicity (DLTs)**: Determine the maximum tolerated dose (MTD) of Selumetinib in combination with Pembrolizumab, as well as the incidence of dose - limiting toxicity.
2. **Adverse Events (AEs)**: Monitor adverse events that occur during treatment, especially serious adverse events.
3. **Treatment Discontinuation**: Evaluate treatment discontinuation due to adverse events.
4. **Pharmacokinetics (PK)**: Analyze the changes in plasma concentrations of Selumetinib and its metabolite N - demethyl - Selumetinib.
5. **Anti - tumor Activity**: Evaluate the objective response rate (ORR) and other efficacy indicators of the combination therapy.

The research background indicates that MEK inhibitors have immunomodulatory effects, and combination with PD - 1 inhibitors may produce a synergistic effect, thereby enhancing anti - tumor effects. However, some previous clinical trial results have shown that this combination therapy did not significantly improve the survival time of patients in certain types of cancers, but instead increased toxic reactions. Therefore, this study hopes to further explore the safety and effectiveness of this combination therapy through detailed dose - escalation trials.